{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:06:56Z","timestamp":1791176816026,"version":"4.1.0"},"reference-count":32,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,1,29]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Veltuzumab is a humanized anti-CD20 monoclonal antibody with complementarity-determining regions (CDRs) identical to rituximab, except for one residue at the 101st position (Kabat numbering) in CDR3 of the variable heavy chain (VH), having aspartic acid (Asp) instead of asparagine (Asn), with framework regions of epratuzumab, a humanized anti-CD22 antibody. When compared with rituximab, veltuzumab has significantly reduced off-rates in 3 human lymphoma cell lines tested, aswell as increased complement-dependent cytotoxicity in 1 of 3 cell lines, but no other in vitro differences. Mutation studies confirmed that the differentiation of the off-rate between veltuzumab and rituximab is related to the single amino acid change in CDR3-VH. Studies of intraperitoneal and subcutaneous doses in mouse models of human lymphoma and in normal cynomolgus monkeys disclosed that low doses of veltuzumab control tumor growth or deplete circulating or sessile B cells. Low- and high-dose veltuzumab were significantly more effective in vivo than rituximab in 3 lymphoma models. These findings are consistent with activity in patients with non-Hodgkin lymphoma given low intravenous or subcutaneous doses of veltuzumab. Thus, changing Asn101 to Asp101 in CDR3-VH of rituximab is responsible for veltuzumab's lower off-rate and apparent improved potency in preclinical models that could translate into advantages in patients.<\/jats:p>","DOI":"10.1182\/blood-2008-07-168146","type":"journal-article","created":{"date-parts":[[2008,10,22]],"date-time":"2008-10-22T01:10:48Z","timestamp":1224637848000},"page":"1062-1070","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":107,"title":["Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody"],"prefix":"10.1182","volume":"113","author":[{"given":"David M.","family":"Goldenberg","sequence":"first","affiliation":[{"name":"Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmund A.","family":"Rossi","sequence":"additional","affiliation":[{"name":"Immunomedics, Morris Plains, NJ; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhona","family":"Stein","sequence":"additional","affiliation":[{"name":"Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Cardillo","sequence":"additional","affiliation":[{"name":"Immunomedics, Morris Plains, NJ; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myron S.","family":"Czuczman","sequence":"additional","affiliation":[{"name":"Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J.","family":"Hernandez-Ilizaliturri","sequence":"additional","affiliation":[{"name":"Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans J.","family":"Hansen","sequence":"additional","affiliation":[{"name":"Immunomedics, Morris Plains, NJ; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Hsing","family":"Chang","sequence":"additional","affiliation":[{"name":"Immunomedics, Morris Plains, NJ; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111722453339500_B1","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3322\/canjclin.56.4.226","article-title":"Targeted therapy of cancer: new prospects for antibodies and immunoconjugates.","volume":"56","author":"Sharkey","year":"2006","journal-title":"CA Cancer J Clin"},{"key":"2019111722453339500_B2","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.exphem.2008.04.018","article-title":"Newer monoclonal antibodies for hematological malignancies.","volume":"36","author":"Castillo","year":"2008","journal-title":"Exp Hematol"},{"key":"2019111722453339500_B3","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1158\/1078-0432.CCR-03-0493","article-title":"Characterization of a new humanized anti-CD20 monoclonal antibody. IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma.","volume":"10","author":"Stein","year":"2004","journal-title":"Clin Cancer Res"},{"key":"2019111722453339500_B4","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1182\/blood-2004-01-0039","article-title":"Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphoma.","volume":"104","author":"Teeling","year":"2004","journal-title":"Blood"},{"key":"2019111722453339500_B5","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/01.cji.0000155050.03916.04","article-title":"Depletion of B cells by a humanized anti-CD20 antibody PRO70769 in Macaca fascicularis.","volume":"28","author":"Vugmeyster","year":"2005","journal-title":"J Immunother"},{"key":"2019111722453339500_B6","article-title":"GA101, a novel therapeutic type II CD20 antibody with outstanding anti-tumor efficacy in non-Hodgkin lymphoma xenograft models and superior B cell depletion.","volume":"19","author":"Umana","year":"2008","journal-title":"Ann Oncol"},{"key":"2019111722453339500_B7","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2008-LB-70","article-title":"Preliminary results of a Phase I study of AME-133v, an Fc-engineered humanized monoclonal antibody, in low-affinity Fc\u03b3RIIIa patients with previously-treated follicular lymphoma.","author":"Forero","year":"2008"},{"key":"2019111722453339500_B8","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1016\/j.molimm.2007.06.151","article-title":"Mechanisms of killing by anti-CD20 monoclonal antibodies.","volume":"44","author":"Glennie","year":"2007","journal-title":"Mol Immunol"},{"key":"2019111722453339500_B9","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1182\/asheducation-2007.1.226","article-title":"Follicular NHL: from antibodies and vaccines to graft-versus-lymphoma effects.","author":"Maloney","year":"2007","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2019111722453339500_B10","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1053\/j.seminhematol.2008.02.007","article-title":"Novel and engineered anti-B-cell monoclonal antibodies for non-Hodgkin's lymphoma.","volume":"45","author":"Martin","year":"2008","journal-title":"Semin Hematol"},{"key":"2019111722453339500_B11","first-page":"449s","article-title":"Low doses of humanized anti-CD20 antibody, IMMU-106 (hA20) in refractory or recurrent NHL: phase I\/II results.","volume":"25","author":"Morschhauser","year":"2007","journal-title":"Proc Am Soc Clin Oncol, J Clin Oncol"},{"key":"2019111722453339500_B12","first-page":"142s","article-title":"Laboratory and clinical studies of high anti-lymphoma potency with anti-CD20 veltuzumab and differentiation from rituximab.","volume":"26","author":"Goldenberg","year":"2008","journal-title":"Proc Am Soc Clin Oncol, J Clin Oncol"},{"key":"2019111722453339500_B13","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/0161-5890(95)00080-1","article-title":"Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia\/lymphoma antibody, LL2.","volume":"32","author":"Leung","year":"1995","journal-title":"Mol Immunol"},{"key":"2019111722453339500_B14","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1586\/14737140.6.10.1341","article-title":"Epratuzumab in the therapy of oncological and immunological diseases.","volume":"6","author":"Goldenberg","year":"2006","journal-title":"Expert Rev Anticancer Ther"},{"key":"2019111722453339500_B15","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.","volume":"65","author":"Mosmann","year":"1983","journal-title":"J Immunol Methods"},{"key":"2019111722453339500_B16","first-page":"5866","article-title":"Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.","volume":"9","author":"Hernandez-Ilizaliturri","year":"2003","journal-title":"Clin Cancer Res"},{"key":"2019111722453339500_B17","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1089\/cbr.2007.371","article-title":"Evaluation of the binding of radiolabeled rituximab to CD20-positive lymphoma cells: an in vitro feasibility study concerning low-dose-rate radioimmunotherapy with the alpha-emitter 227Th.","volume":"22","author":"Melhus","year":"2007","journal-title":"Cancer Biother Radiopharm"},{"key":"2019111722453339500_B18","unstructured":"Prescribing information for rituximab 2008 Accessed April 24, 2008 Online document at http:\/\/www.rituxan.com\/ra\/prescribing.info.jsp"},{"key":"2019111722453339500_B19","doi-asserted-by":"crossref","first-page":"5044","DOI":"10.1200\/JCO.2005.13.821","article-title":"Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.","volume":"23","author":"Leonard","year":"2005","journal-title":"J Clin Oncol"},{"key":"2019111722453339500_B20","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1200\/JCO.2006.05.6291","article-title":"Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma.","volume":"24","author":"Strauss","year":"2006","journal-title":"J Clin Oncol"},{"key":"2019111722453339500_B21","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1002\/cncr.23890","article-title":"Durable complete responses with combination therapy of epratuzumab and rituximab: final results of an international multicenter, phase II study, in recurrent indolent non-Hodgkin lymphoma.","volume":"113","author":"Leonard","year":"2008","journal-title":"Cancer"},{"key":"2019111722453339500_B22","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1200\/JCO.2000.18.17.3135","article-title":"Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.","volume":"18","author":"Davis","year":"2000","journal-title":"J Clin Oncol"},{"key":"2019111722453339500_B23","first-page":"29","article-title":"Characterization of novel murine anti-CD20 monoclonal antibodies and their comparison to 2B8 and c2B8 (rituximab).","volume":"31","author":"Nishida","year":"2007","journal-title":"Int J Oncol"},{"key":"2019111722453339500_B24","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.4049\/jimmunol.161.7.3242","article-title":"Identification of a cytoplasmic region of CD20 required for its redistribution to a detergent-insoluble membrane compartment.","volume":"161","author":"Polyak","year":"1998","journal-title":"J Immunol"},{"key":"2019111722453339500_B25","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1182\/blood.V99.9.3256","article-title":"Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes: heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure.","volume":"99","author":"Polyak","year":"2002","journal-title":"Blood"},{"key":"2019111722453339500_B26","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood-2005-04-1769","article-title":"Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor.","volume":"107","author":"Perosa","year":"2006","journal-title":"Blood"},{"key":"2019111722453339500_B27","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.molimm.2006.05.007","article-title":"Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab.","volume":"44","author":"Carnahan","year":"2007","journal-title":"Mol Immunol"},{"key":"2019111722453339500_B28","doi-asserted-by":"crossref","first-page":"362","DOI":"10.4049\/jimmunol.177.1.362","article-title":"The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.","volume":"177","author":"Teeling","year":"2006","journal-title":"J Immunol"},{"key":"2019111722453339500_B29","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1016\/j.molimm.2008.01.034","article-title":"Crystal structure of chimeric antibody C2H7 Fab in complex with a CD20 peptide.","volume":"45","author":"Du","year":"2008","journal-title":"Mol Immunol"},{"key":"2019111722453339500_B30","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1182\/blood-2007-09-111781","article-title":"Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study.","volume":"111","author":"Coiffier","year":"2008","journal-title":"Blood"},{"key":"2019111722453339500_B31","doi-asserted-by":"crossref","first-page":"5486","DOI":"10.1182\/blood-2007-10-117671","article-title":"First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase I\/II trial.","volume":"111","author":"Hagenbeek","year":"2008","journal-title":"Blood"},{"key":"2019111722453339500_B32","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1365-2141.2007.06916.x","article-title":"Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody.","volume":"140","author":"Bleeker","year":"2007","journal-title":"Br J Haematol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/113\/5\/1062\/1309106\/zh800509001062.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/113\/5\/1062\/1309106\/zh800509001062.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T16:55:58Z","timestamp":1684601758000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/113\/5\/1062\/25652\/Properties-and-structurefunction-relationships-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,29]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,1,29]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2008-07-168146","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,29]]}}}